There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sonnet BioTherapeutics Holdings (SONN – Research Report) and Tarsus Pharmaceuticals (TARS – Research Report) with bullish sentiments. Sonnet BioTherapeutics Holdings (SONN) Chardan Capital analyst Keay Nakae reiterated a Buy rating on Sonnet BioTherapeutics Holdings yesterday and set a price target of $2.50. The company's shares closed last Thursday at $0.25, close to its 52-week low of $0.24. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-sonnet-biotherapeutics-holdings-sonn-tarsus-pharmaceuticals-tars?utm_source=advfn.com&utm_medium=referral